Roche Holding stock trades at EUR 386.70 with CHF 316.0 billion market cap

Published on 10/12/2026 at 14:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock costs EUR 386.70 on October 12, 2026, with CHF 316.0 billion value. Third-quarter sales are due October 22, 2026 at 14:00 CEST.

Key points in brief

Roche Holding traded at EUR 386.70 at Lang & Schwarz on October 12, 2026 at 2:29 p.m. CEST.
The bid was EUR 386.65 and the ask EUR 386.75.
Market capitalization was CHF 316.0 billion and the P/E ratio was 23.52.
Roche's next third-quarter sales update is scheduled for October 22, 2026 at 14:00 CEST.
Novartis and Sanofi provide the comparison points with P/E ratios of 21.95 and 22.29.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (CH1499059983) was trading at EUR 386.70 at Lang & Schwarz on October 12, 2026 at 2:29 p.m. CEST, with a CHF 316.0 billion market capitalization as of 2:10 p.m. CEST. The quote put the Swiss healthcare group at a concrete valuation marker while its next sales update moved closer on the calendar.

Price sits between bid and ask

The Lang & Schwarz bid was EUR 386.65 and the ask EUR 386.75 at 2:29 p.m. CEST on October 12, 2026. That five-cent spread places the visible market around the quoted price and gives investors a direct intraday liquidity reference.

Roche's primary market is SIX, where the company trades under the Roche Holding name. Its business combines pharmaceuticals and diagnostics, so the share price reflects both drug development and laboratory technology exposure.

Valuation has two market markers

The finance quote showed a P/E ratio of 23.52 and a market capitalization of CHF 316.0 billion at 2:10 p.m. CEST on October 12, 2026. The valuation can be read against other large healthcare groups without converting the Swiss-franc figures into euros.

The next company-specific date is more immediate than a long-range valuation debate. Roche's investor calendar schedules the third-quarter sales update for October 22, 2026 at 14:00 CEST, according to Roche.

Comparison with peers on October 12, 2026

Roche Holding (SIX, CHF): P/E 23.52, market capitalization CHF 316.0 billion

Novartis (SIX, CHF): plus 0.45 percent, P/E 21.95, market capitalization CHF 227.4 billion

Sanofi (Euronext Paris, EUR): plus 0.96 percent, P/E 22.29, market capitalization EUR 86.7 billion

Sales update sets the next date

The October 22 event is a sales presentation rather than a full quarterly profit-and-loss release. That distinction matters because investors will first receive an operating update, while the valuation markers remain the market capitalization and P/E ratio already visible in the current quote.

Roche's diagnostics division adds a second earnings driver alongside its pharmaceutical pipeline. The combination gives the stock a broader operating profile than a pure drug developer, but the upcoming sales figure will still be the next dated company checkpoint.

Trading continues on SIX

For investors tracking the Swiss listing, the current euro quotation offers a German-market view of Roche Holding while the valuation comparison remains in the original currencies of the quoted companies. The trading picture is therefore best read through the EUR 386.70 Lang & Schwarz price, the CHF 316.0 billion market capitalization and the 23.52 P/E ratio.

The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.